Recursion Pharmaceuticals Announces 2 Key Investigational Oncology Drugs Advancing To Clinical Trials, Targeting High Unmet Needs In Hematologic Malignancies, Small-Cell Lung Cancer, & More
Recursion Pharmaceuticals Announces 2 Key Investigational Oncology Drugs Advancing To Clinical Trials, Targeting High Unmet Needs In Hematologic Malignancies, Small-Cell Lung Cancer, & More
- REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitors
- REC-4539, a potential best-in-class LSD1 inhibitor, is the first designed to be reversible and CNS penetrant for small-cell lung cancer
- REC-3565是一种潜在的最佳MALT1抑制剂，适用于多种血液学适应症，旨在降低高胆红素血症的风险，这是其他MALT1抑制剂的常见副作用。
- REC-4539，一种潜在的最佳LSD1抑制剂，是首个设计为可逆且能够渗透中枢神经系统的小细胞肺癌药物。
Salt Lake City, UT, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has cleared a clinical trial application (CTA) for a Phase 1 clinical trial of REC-3565, a potential best-in-class MALT1 inhibitor for B-cell malignancies. For REC-3565, the total addressable population could include a range of hematological indications, with approximately 41,000 relapsed and/or refractory (R/R) patients with chronic lymphocytic leukemia (CLL) and B-cell lymphomas in the US+EU5 annually.
犹他州盐湖城，2025年1月7日（全球新闻网）——Recursion（纳斯达克：RXRX），一家领先的临床阶段科技生物公司，致力于解码生物学以工业化药物发现，今天宣布，英国药品和健康产品监管局（MHRA）已批准一项临床试验申请（CTA），用于REC-3565的第一期临床试验。REC-3565是一种潜在的最佳MALT1抑制剂，针对b细胞恶性肿瘤。对于REC-3565，潜在的适应人群可能包括多种血液学适应症，每年在美国和欧洲五国（EU5）中大约有41,000名复发和/或难治性（R/R）慢性淋巴细胞白血病（CLL）及b细胞淋巴瘤患者。
Recursion also announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for a Phase 1/2 clinical trial of REC-4539, a potential best-in-class LSD1 inhibitor for small-cell lung cancer (SCLC) and other potential indications. For REC-4539, the total addressable population in the US+EU5 for extensive stage SCLC is approximately 45,000 patients annually.
Recursion还宣布，美国食品和药品管理局（FDA）已批准一项针对REC-4539的第一/二期临床试验的新药研究（IND）申请，REC-4539是一种潜在的最佳LSD1抑制剂，适用于小细胞肺癌（SCLC）和其他潜在适应症。对于REC-4539，针对广泛期小细胞肺癌在美国和欧洲五国（EU5）的潜在适应人群每年约为45,000名患者。